Latest From SillaJen Inc.
The planned merger between Genexine and ToolGen, which was poised to create a major Korean biotech entity, has collapsed amid recent generally weak investor sentiment over the sector. But the two sides will maintain their collaborations for new drug development going forward, with a focus on gene and cell therapies.
Inovio is poised to become the first US-listed company to dual-list in South Korea, as CEO tells Scrip it is seeking to increase its presence and find new opportunities in Asia, while benefiting from strong investor interest in the country’s "very exciting" and vibrant biotech industry.
A late-phase assessment of the oncolytic virus in liver cancer patients was stopped early for futility but Transgene thinks the failure is an isolated event.
AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- SillaJen Co. Ltd.
- SillaJen Biotherapeutics
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- SillaJen Inc.
- Senior Management
- Eun-Sang Moon, CEO
- Contact Info
Phone: 51 510 7550
6F, 252, Geumjeong-ro
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.